GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (NAS:CRIS) » Definitions » Piotroski F-Score

Curis (CRIS) Piotroski F-Score

: 4 (As of Today)
View and export this data going back to 2000. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Curis has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Curis's Piotroski F-Score or its related term are showing as below:

CRIS' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 4

During the past 13 years, the highest Piotroski F-Score of Curis was 5. The lowest was 2. And the median was 4.


Curis Piotroski F-Score Historical Data

The historical data trend for Curis's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 3.00 5.00 4.00

Curis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 3.00 4.00 4.00 4.00

Competitive Comparison

For the Biotechnology subindustry, Curis's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, Curis's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Curis's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -11.559 + -11.961 + -12.181 + -11.712 = $-47.41 Mil.
Cash Flow from Operations was -12.199 + -7.868 + -8.181 + -10.186 = $-38.43 Mil.
Revenue was 2.297 + 2.197 + 2.833 + 2.696 = $10.02 Mil.
Gross Profit was 2.273 + 2.123 + 2.773 + 2.642 = $9.81 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(108.848 + 94.544 + 84.308 + 89.975 + 77.282) / 5 = $90.9914 Mil.
Total Assets at the begining of this year (Dec22) was $108.85 Mil.
Long-Term Debt & Capital Lease Obligation was $1.49 Mil.
Total Current Assets was $60.91 Mil.
Total Current Liabilities was $13.52 Mil.
Net Income was -16.109 + -15.94 + -13.294 + -11.329 = $-56.67 Mil.

Revenue was 2.057 + 2.393 + 2.825 + 2.887 = $10.16 Mil.
Gross Profit was 1.975 + 2.351 + 2.763 + 2.816 = $9.91 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(162.301 + 140.739 + 128.834 + 122.854 + 108.848) / 5 = $132.7152 Mil.
Total Assets at the begining of last year (Dec21) was $162.30 Mil.
Long-Term Debt & Capital Lease Obligation was $2.80 Mil.
Total Current Assets was $92.12 Mil.
Total Current Liabilities was $10.01 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Curis's current Net Income (TTM) was -47.41. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Curis's current Cash Flow from Operations (TTM) was -38.43. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-47.413/108.848
=-0.43558908

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-56.672/162.301
=-0.34917838

Curis's return on assets of this year was -0.43558908. Curis's return on assets of last year was -0.34917838. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Curis's current Net Income (TTM) was -47.41. Curis's current Cash Flow from Operations (TTM) was -38.43. ==> -38.43 > -47.41 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=1.489/90.9914
=0.01636418

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=2.8/132.7152
=0.02109781

Curis's gearing of this year was 0.01636418. Curis's gearing of last year was 0.02109781. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=60.908/13.517
=4.50602944

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=92.119/10.013
=9.19994008

Curis's current ratio of this year was 4.50602944. Curis's current ratio of last year was 9.19994008. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Curis's number of shares in issue this year was 5.777. Curis's number of shares in issue last year was 4.823. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=9.811/10.023
=0.97884865

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=9.905/10.162
=0.9747097

Curis's gross margin of this year was 0.97884865. Curis's gross margin of last year was 0.9747097. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=10.023/108.848
=0.09208254

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=10.162/162.301
=0.06261206

Curis's asset turnover of this year was 0.09208254. Curis's asset turnover of last year was 0.06261206. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Curis has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Curis  (NAS:CRIS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Curis Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Curis's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Curis (CRIS) Business Description

Traded in Other Exchanges
Address
128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Executives
Jonathan B. Zung officer: CDO C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Anne Elizabeth Borgman director 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Kenneth I Kaitin director C/O TUFTS CNTR FOR THE STUDY OF DRUG DEV, 75 KNEELAND ST, SUITE 1100, BOSTON MA 02111
Martyn D Greenacre director 41 MOORES ROAD, FRAZER PA 19355
Robert Martell officer: Head of Research & Development 4 MAGUIRE ROAD, LEXINGTON MA 02421
Diantha Duvall officer: CFO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James E Dentzer director, officer: President & CEO C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
William Steinkrauss officer: VP, Finance & Treasurer, other: Principal Accounting Officer C/O CURIS, INC.,, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Lori Anne Kunkel director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Fattaey Ali Ph.d. officer: President & COO C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Aurigene Discovery Technologies Ltd 10 percent owner 39-40 KIADB INDUSTRIAL AREA, PHASE II, ELECTRONIC CITY HOSUR ROAD, BANGALORE (KARNATAKA) K7 560100
David Tuck officer: Sr. Vice-President C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421